Compound of Formula IVa or IVb: ** ** Formula or a pharmaceutically acceptable salt form thereof, wherein: R is selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cy, C1-6 haloalkyl, halosulfanyl, CN, NO2, OR a1, SR a1, C (O) R b1, C (O) NRc1Rd1, C (O) OR a1, OC (O) R b1, OC (O) NRc1Rd1, C (> = NR) NRc1Rd1, NR c1 C (> = NR) NRc1Rd1, NRc1Rd1, NR c1 C (O) R b1, NR c1 C (O) OR a1, NR c1 C (O) NRc1Rd1, NR c1 (O) R b1, NR c1 S (O) 2Rb1, S (O) Rb1 , S (O) NRc1Rd1, S (O) 2Rb1 and S (O) 2NRc1Rd1 wherein said C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halo, C1-6 alkyl, C2-6 alkenyl, C2- alkynyl 6, Cy, C1-6 haloalkyl, halosulfanyl, CN, NO2, OR a1, SR a1, C (O) R b1, C (O) NRc1Rd1, C (O) OR a1, OC (O) R b1, OC (O) NRc1Rd1, C (> = NR) NRc1Rd1, NR c1 C (> = NR) NRc1Rd1, NRc1Rd1, NR c1 C (O) R b1, NR c1 C (O) OR a1, NR c1 C (O) NRc1Rd1, NR c1 (O) R b1, NR c1 S (O) 2Rb1, S (O ) R b1, S (O) NRc1Rd1, S (O) 2Rb1 and S (O) 2NRc1Rd1 Q1, Q2 and Q3 are independently selected from CRQ and N RQ is independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cy, C1-6 haloalkyl, halosulfanyl, CN, NO2, OR a1, SR a1, C (O) Rb1, C ( O) NRc1Rd1, C (O) OR a1, OC (O) R b1, OC (O) NRc1Rd1, C (> = NR) NRc1Rd1, NR c1 C (> = NR) NRc1Rd1, NRc1Rd1, NR c1 C (O) R b1, NR c1 C (O) a1, NR c1 C (O) NRc1Rd1, NR c1 (O) R b1, NR c1 S (O) 2Rb1, S (O) R b1, S (O) NRc1Rd1, S (O) 2Rb1 and S (O) 2NRc1Rd1 wherein said C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl is optionally substituted with 1, 2, 3, 4 or 5 substituents selected from halo, C1-6 alkyl, C2-6 alkenyl, C2- alkynyl 6, Cy, C1-6 haloalkyl, halosulfanyl, CN, NO2, OR a1, SR a1, C (O) R b1, C (O) NRc1Rd1, C (O) OR a1, OC (O) R b1, OC (O) NRc1Rd1, C (> = NR) NRc1Rd1, NR c1 C (> = NR) NRc1Rd1, NRc1Rd1, NR c1 C (O) R b1, NR c1 C (O) OR a1, NR c1 C (O) NRc1Rd1, NR c1 (O) R b1, NR c1 S (O) 2Rb1, S (O ) R b1, S (O) NRc1Rd1, S (O) 2Rb1 and S (O) 2NRc1Rd1.Compuesto de Fórm
